MA29784B1 - Combinaisons contenant dmxaa pour traiter le cancer - Google Patents

Combinaisons contenant dmxaa pour traiter le cancer

Info

Publication number
MA29784B1
MA29784B1 MA30753A MA30753A MA29784B1 MA 29784 B1 MA29784 B1 MA 29784B1 MA 30753 A MA30753 A MA 30753A MA 30753 A MA30753 A MA 30753A MA 29784 B1 MA29784 B1 MA 29784B1
Authority
MA
Morocco
Prior art keywords
treat cancer
combinations
combinations containing
dmxaa
containing dmxaa
Prior art date
Application number
MA30753A
Other languages
English (en)
Inventor
Colin Green
Lloyd Kelland
Gail Rowlinson-Busza
Original Assignee
Antisoma Plc
Antisoma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisoma Plc, Antisoma Res Ltd filed Critical Antisoma Plc
Publication of MA29784B1 publication Critical patent/MA29784B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'INVENTION CONCERNE DES COMBINAISONS DE LA CATÉGORIE DES ACIDES XANTHÉNONE-ACÉTIQUES, TELS QU'ACIDE 5,6-DIMÉTHYLXANTHÉNONE-4-ACÉTIQUE (DMXAA) ET DES INHIBITEURS DU TRAJET DE SIGNALISATION DE EGFR. ELLE CONCERNE, PLUS PARTICULIÈREMENT, L'UTILISATION DE CES COMBINAISONS AFIN DE TRAITER LE CANCER, AINSI QUE DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMBINAISONS.
MA30753A 2005-08-26 2008-03-17 Combinaisons contenant dmxaa pour traiter le cancer MA29784B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0517387.7A GB0517387D0 (en) 2005-08-26 2005-08-26 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
MA29784B1 true MA29784B1 (fr) 2008-09-01

Family

ID=35198384

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30753A MA29784B1 (fr) 2005-08-26 2008-03-17 Combinaisons contenant dmxaa pour traiter le cancer

Country Status (16)

Country Link
US (1) US20100104565A1 (fr)
EP (1) EP1931331A1 (fr)
JP (1) JP2009506020A (fr)
KR (1) KR20080048488A (fr)
CN (1) CN101296695A (fr)
AU (1) AU2006283376A1 (fr)
BR (1) BRPI0614964A2 (fr)
CA (1) CA2620447A1 (fr)
EC (1) ECSP088242A (fr)
GB (1) GB0517387D0 (fr)
IL (1) IL189377A0 (fr)
MA (1) MA29784B1 (fr)
NO (1) NO20080650L (fr)
RU (1) RU2404765C2 (fr)
TN (1) TNSN08057A1 (fr)
WO (1) WO2007023307A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004505047A (ja) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
US8287346B2 (en) * 2008-11-03 2012-10-16 Cfph, Llc Late game series information change
EP3071209A4 (fr) * 2013-11-19 2017-08-16 The University of Chicago Utilisation d'un agoniste de sting en tant que traitement anti-cancéreux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations

Also Published As

Publication number Publication date
CA2620447A1 (fr) 2007-03-01
NO20080650L (no) 2008-05-13
RU2404765C2 (ru) 2010-11-27
RU2008111493A (ru) 2009-10-10
AU2006283376A1 (en) 2007-03-01
EP1931331A1 (fr) 2008-06-18
BRPI0614964A2 (pt) 2016-09-13
TNSN08057A1 (en) 2009-07-14
KR20080048488A (ko) 2008-06-02
WO2007023307A1 (fr) 2007-03-01
GB0517387D0 (en) 2005-10-05
US20100104565A1 (en) 2010-04-29
CN101296695A (zh) 2008-10-29
JP2009506020A (ja) 2009-02-12
IL189377A0 (en) 2008-06-05
ECSP088242A (es) 2008-08-29

Similar Documents

Publication Publication Date Title
MA29784B1 (fr) Combinaisons contenant dmxaa pour traiter le cancer
MA31167B1 (fr) Inhibiteurs de l'activite de akt
EA200702455A1 (ru) Модуляторы индоламин 2,3-диоксигеназы и способы их применения
MA30762B1 (fr) Anticorps specifiques du prlr et leurs utilisations
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
HN2002000152A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
MA49628B1 (fr) Processus pour la purification de l'acide hyaluronique
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
MA34909B1 (fr) Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
MA31675B1 (fr) Petites molecules contenant du bore
WO2007075598A3 (fr) N-hydroxyamidinoheterocycles en tant que modulateurs d'indoleamine 2,3-dioxygenase
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
WO2007095050A3 (fr) N-hydroxyguanidines comme modulateurs de l'indolamine 2,3-dioxygénase
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
BRPI0720991A8 (pt) Preparação da romidepsina
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
UY30322A1 (es) Moduladores bencimidazólicos de vr1
MA33075B1 (fr) Composition destinee a la regulation du metabolism des lipides
IL172773A0 (en) Formulations for the treatment of arhritis conditions